A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/545902

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients who suffer a moderate or severe head injury (traumatic brain injury) have a 50% chance of having a long term neurological disability or death. Erythropoietin is a medication which encourages red blood cell formation but its other beneficial effects are likely to improve outcomes after traumatic brain injury. This study will examine the safety and effects of erythropoietin on long term neurological function in patients who have suffered a traumatic brain injury.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2015

Funding Scheme: NHMRC Project Grants

Funding Amount: $1,950,735.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Intensive Care

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

erythropoietin | intensive care | neurotrauma | randomised controlled trial | traumatic brain injury

Related Links